Elazar Rabbani, PhD
Chairman of the Board of Directors & Chief Executive Officer
Dr. Elazar Rabbani, PhD is an Enzo Biochem founder and has served as the Company's Chairman of the Board and Chief Executive Officer since its inception in 1976 and Secretary since November 25, 2009. Dr. Rabbani has authored numerous scientific publications in the field of molecular biology, in particular, nucleic acid labeling and detection. He is also the lead inventor of many of the Company's pioneering patents covering a wide range of technologies and products. Dr. Rabbani received his Bachelor of Arts degree from New York University in Chemistry and his Ph.D. in Biochemistry from Columbia University. He is a member of the American Society for Microbiology.
Rebecca Fischer was appointed as an Independent Director of the Company and has agreed to serve on the Audit, Compensation and Nominating/Governance Committees. Ms. Fischer is currently the Chief Financial Officer of NYC Health + Hospitals / Bellevue, a position she has held since 2017. She is directly involved in guiding Bellevue and its leaders through complex government and private reimbursement practices and is responsible for all budgeting, affiliation management, accounts receivable, and grant management functions for the hospital. Ms. Fischer began her career at Bellevue as Associate Director in 2003, became Associate Executive Director in 2011, and was promoted to Deputy CFO in 2016. Her prior experience includes positions at New York Presbyterian Hospital, Columbia University Medical Center, the Center for State Health Policy at Rutgers University, and the New York City Office of Management and Budget. Ms. Fischer received her undergraduate degree cum laude from Cornell University and her Master of Public Administration in Health Policy and Management from New York University, where she was a recipient of the Robert F. Wagner, Jr. Fellowship.
Dov Perlysky has been a Director of the Company since September 2012 and since January 17, 2013 has served on the Audit, Nominating/Governance and Audit Committees. He currently serves as Compensation Committee Chairman. Mr. Perlysky has served as a member of the board of directors of Pharma-Bio Serv, Inc. since 2004 and as a member of the board of directors of Highlands State Bank since 2010. Mr. Perlysky has also been the managing member of Nesher, LLC, a private investment firm, since 2000 and a director of Engex, Inc., a closed-end mutual fund, since 1999. From 1998 until 2002, Mr. Perlysky was a vice president in the private client group of Laidlaw Global Securities, a registered broker-dealer. Mr. Perlysky received his B.S. in Mathematics and Computer Science from the University of Illinois in 1985 and a Masters in Management from the J.L. Kellogg School of Management of Northwestern University in 1991.
Mary Tagliaferri, MD
Dr. Tagliaferri is currently Executive Clinical Fellow and Senior Vice President and she was previously Chief Medical Officer at Nektar Therapeutics, a leading research-based biopharmaceutical company that discovers and develops innovative medicines in areas of high unmet medical need including treatments for cancer and auto-immune disease. Previously, she served as Chief Medical Officer and Chief Regulatory Officer for Kanglaite-USA and was Co-Founder, President and Board Member of Bionovo, Inc. She earned her Bachelor of Science degree at Cornell University and her medical degree at the University of California, San Francisco. Dr. Tagliaferri was named to the Women who Lead in Life Sciences and Most Influential Women in Business lists by the San Francisco Business Times in 2019 and was recognized as Woman of the Year, 2012, by the State of California, Assembly District 14. She has been lead author or contributor to approximately 70 journal publications.
Ian B. Walters, MD
Dr. Walters is an experienced entrepreneur and drug developer with leadership in the development of over 30 drugs in multiple therapeutic areas involving diverse technologies, leading to five new oncology drug approvals. His previous positions include Executive Director of Global Oncology Clinical Research and Business Development for Bristol-Myers Squibb, and Medical Director at Millennium Pharmaceuticals. Dr. Walters currently is CEO and Director of Portage Biotech, a publicly traded clinical stage biopharmaceutical company developing an innovative portfolio of immuno-oncology assets. He is also founder of seven of Portage’s portfolio companies.
Dr. Walters holds an MBA from the Wharton School of the University of Pennsylvania. He received his MD at the Albert Einstein College of Medicine and completed doctoral training in experimental medicine at The Rockefeller University. Dr. Walters has been the lead author or contributor to approximately 60 journal publications.